Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$4.51 USD
-0.02 (-0.33%)
Updated Apr 22, 2024 11:54 AM ET
After-Market: $4.56 +0.06 (1.22%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Autolus Therapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 6 | 2 | 2 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 6 | 2 | 2 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 181 | 174 | 167 | 170 | 149 |
Income After Depreciation & Amortization | -180 | -168 | -165 | -168 | -146 |
Non-Operating Income | 16 | 4 | 0 | 2 | 7 |
Interest Expense | 45 | 9 | 1 | 0 | 0 |
Pretax Income | -208 | -173 | -166 | -166 | -139 |
Income Taxes | 0 | -24 | -24 | -24 | -15 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -208 | -149 | -142 | -142 | -124 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -208 | -149 | -142 | -142 | -124 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -173 | -161 | -157 | -162 | -141 |
Depreciation & Amortization (Cash Flow) | 7 | 7 | 8 | 6 | 5 |
Income After Depreciation & Amortization | -180 | -168 | -165 | -168 | -146 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 173.94 | 94.99 | 72.04 | 51.56 | 43.07 |
Diluted EPS Before Non-Recurring Items | -1.20 | -1.57 | -1.97 | -2.76 | -2.88 |
Diluted Net EPS (GAAP) | -1.20 | -1.57 | -1.97 | -2.76 | -2.88 |
Fiscal Year end for Autolus Therapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.41 | 0.00 | 1.29 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.41 | 0.00 | 1.29 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 40.89 | 48.23 | 47.89 | 44.39 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -40.89 | -47.82 | -47.89 | -43.10 |
Non-Operating Income | NA | 6.20 | 2.05 | 3.89 | 4.23 |
Interest Expense | NA | 30.13 | 5.01 | 5.02 | 4.91 |
Pretax Income | NA | -64.81 | -50.79 | -49.02 | -43.78 |
Income Taxes | NA | 12.36 | -4.94 | -3.47 | -3.97 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -77.17 | -45.85 | -45.55 | -39.81 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -77.17 | -45.85 | -45.55 | -39.81 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 174.03 | 173.98 | 173.86 | 173.83 |
Diluted EPS Before Non-Recurring Items | NA | -0.44 | -0.26 | -0.26 | -0.23 |
Diluted Net EPS (GAAP) | NA | -0.45 | -0.26 | -0.26 | -0.23 |